Carisma Therapeutics (CARM) announced the upcoming presentation of new pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte, or CAR-M, therapy for the treatment of hepatocellular carcinoma, developed in collaboration with Moderna (MRNA). The abstract presents the first pre-clinical data on the development candidate targeting Glypican-3, a tumor-associated antigen commonly expressed in HCC. This novel off-the-shelf approach reprograms endogenous myeloid cells in vivo using lipid nanoparticles to deliver mRNA encoding CARs. The data show that this in vivo CAR-M therapy has significant potential as a treatment for GPC3+ solid tumors, including HCC.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CARM:
- Carisma Therapeutics, Inc. (CARM) Q3 Earnings Cheat Sheet
- Leadership Transition at Carisma Therapeutics’ Board of Directors
- Alphabet upgraded, Boeing downgraded: Wall Street’s top analyst calls
- Carisma Therapeutics initiated with a Buy at EF Hutton
- Carisma Therapeutics and Moderna expand collaboration to develop CAR-M therapies